Mainz Biomed N.V. MYNZ 深 滬
等待開盤 03-26 09:30:00 美东时间
0.8441
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.8441
- 總市值 1056.42万
- 52周最高 4.797
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.5476
- 委 比 0.00%
- 總股本 1251.53万
- 歷史最高 1200.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.5476
- 每 手 1
- 風險率 0.76%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Mainz Biomed changes ticker symbol to "QUCY"
Mainz Biomed (QUCY), doing business as Quantum Cyber, has officially changed its ticker symbol to "QUCY" on the Nasdaq Capital Market. Further, the company’s name will change to Quantum Cyber N.V., ef...
03-13 19:55
Mainz Biomed Appoints Robert Liscouski As Chairman Of Its Board Of Directors; Co Plans To Change Its Name To Quantum Cyber And Nasdaq Ticker Symbol To QUCY, Effective March 12
Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors.
03-11 19:34
Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors
Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company, announced the appointment of Robert P. Liscouski as Chairman of its Board of Directors and planned to change its name to Quantum Cyber and its Nasdaq ticker symbol to QUCY starting March 12, 2026. The changes will become official at an extraordinary general meeting in April 2026. Liscouski, a seasoned executive with expertise in cybersecurity, AI, and critical infrastructu...
03-11 11:30
Mainz Biomed To Present Poster Titled BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS At Digestive Disease Week In Chicago
Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the renowned Digestive Disease Week (DDW) 2026 in
02-24 20:44
Mainz Biomed Raises $6M Private Placement To Fund Operations And Shift Focus To Pancreatic Cancer Screening
Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, announced a series of strategic transactions designed to strengthen its liquidity position,
02-17 20:35
Mainz Biomed Announces 6.0 USD Million Private Placement and Strategic Update
Mainz Biomed secures $6M private placement to focus on pancreatic cancer detection in the U.S., sell colorectal cancer assets, and wind down German operations, aiming to stabilize and grow its业务 while exploring strategic alternatives.
02-17 12:30
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CFO William Caragol
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for CFO William Caragol Mainz Biomed NV has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists William J. Caragol as the beneficial owner in his role as Chief Financial
01-27 05:09
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for Director Heinrich Dreismann
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for Director Heinrich Dreismann Mainz Biomed NV has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Heinrich Dreismann as the beneficial owner in his capacity as Dire
01-27 05:06
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for Director Gregory J. Tibbitts
Mainz Biomed NV Files Initial Statement of Beneficial Ownership for Director Gregory J. Tibbitts Mainz Biomed NV has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Gregory J. Tibbitts as the beneficial owner in his capacity as Di
01-27 05:04
Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting
Mainz Biomed will present its study on a blood-based mRNA signature combined with AI to differentiate PDAC from IPMN at the AACR 2026 meeting in San Diego, aiming to advance pancreatic cancer screening and reduce mortality.
01-14 14:15
